Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial. - The Lancet

Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial.  The Lancet

Comments

Post a Comment

Popular posts from this blog

Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC - Cancer Network

Image
In recent years, health care providers have become increasingly concerned around the use of stereotactic radiation for lung cancers that are found near the center of a patient's chest, according to an expert. As a result, Anand Swaminath, MD, and colleagues, wanted not only to assess the efficacy, but also the safety of stereotactic body radiation in a group of patients with inoperable non-small cell lung cancer (NSCLC). Swaminath, an associate professor, clinician scientist, and radiation oncologist at Juravinski Cancer Centre in Ontario, Canada, spoke with CancerNetwork ® during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting and discussed why they compared stereotactic body radiotherapy with a 3-week conventional hypofractionated radiotherapy regimen for patients with stage I medically inoperable NSCLC. Transcript: The standard of care right now for stage I lung cancer is to have surgery. But radiation is a suitable alternative to surgery, and a specifi
Read more